CORT - コ―セプト・セラピュ―ティクス （Corcept Therapeutics Incorporated） コ―セプト・セラピュ―ティクスCORTのチャート
CORTの企業情報
| symbol | CORT |
|---|---|
| 会社名 | Corcept Therapeutics Inc （コ―セプト・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 コーセプト・セラピューティクス（Corcept Therapeutics Incorporated）は重篤な代謝と精神・腫瘍疾患の治療薬の発見・開発・商業化に従事する製薬会社である。同社はグルココルチコイド受容体（GR）においてアンタゴニストとして作用することによりコルチゾールの効果を調節する化合物であるミフェプリストンを開発する。同社は選択的コルチゾールモジュレーターであるCORT125134の2つの臨床試験を実施する。同社はクッシング症候群患者の治療法として、CORT125134を検討する。第2の試験では、固形腫瘍がん患者を治療するためのCORT125134とナブパクリタキセルの組み合わせが検討される。 コ―セプト・セラピュ―ティクスは米国の製薬会社。代謝異常、精神疾患、がん細胞などの治療薬の開発と商品化に従事。主要製品はクッシング病を患う成人の高血糖症治療薬｢Korlym｣。また、心因性うつ病治療薬として｢Korlym｣の有効成分であるミフェプリストンの開発も進める。 Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA. |
| 本社所在地 | 149 Commonwealth Drive Menlo Park CA 94025 USA |
| 代表者氏名 | James N. Wilson ジェームズ・N・ウィルソン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-327-3270 |
| 設立年月日 | 35916 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 1982年 |
| 従業員数 | 136人 |
| url | www.corcept.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cort |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 77.13800 |
| 終値（lastsale） | 13.295 |
| 時価総額（marketcap） | 1542901262.39 |
| 時価総額 | 時価総額（百万ドル） 1591.063 |
| 売上高 | 売上高（百万ドル） 216.01400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1431.118 |
| 当期純利益 | 当期純利益（百万ドル） 180.97500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Corcept Therapeutics Incorporated revenues increased 90% to $120M. Net income increased from $17M to $35.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from $0.15 to $0.31. |
CORTのテクニカル分析
CORTのニュース
Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates 2020/05/04 23:05:06 Zacks Investment Research
Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace 2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
Cushing's Syndrome Pipeline Insight, 2020 Featuring Novartis Pharmaceuticals, Cortendo AB, Corcept Therapeutics and HRA Pharma - ResearchAndMarkets.com 2020/05/01 16:31:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Cushing's Syndrome Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Cushing's Syndrome market. A detailed picture of the Cushing's Syndrome pipeline landscape is provided, which includes the disease overview and Cushing's Syndrome treatment guidelines. The assessment part of the report embraces in-depth Cushi
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice 2020/04/27 16:00:07 Zacks Investment Research
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Corcept Therapeutics' Shares March Higher, Can It Continue? 2020/04/13 12:31:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor in Corcept Therapeutics.
Why You Shouldn't Bet Against Corcept Therapeutics (CORT) Stock 2020/04/02 13:51:00 Zacks Investment Research
Corcept Therapeutics (CORT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Corcept (CORT) Down 24.9% Since Last Earnings Report: Can It Rebound? 2020/03/21 15:30:56 Zacks Investment Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT) 2020/02/24 17:41:00 Business Wire
SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)---- $CORT #ClassAction--Shareholder rights law firm Robbins LLP is investigating the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the Securities Exchange Act of 1934. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders. Corcept's drug Korylm is a cortisol receptor blocker used to control
Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y 2020/02/21 19:25:00 Zacks Investment Research
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
Why Corcept (CORT) Could Beat Earnings Estimates Again 2020/02/19 17:10:06 Zacks Investment Research
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT) 2020/02/24 17:41:00 Business Wire
SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)---- $CORT #ClassAction--Shareholder rights law firm Robbins LLP is investigating the officers and directors of Corcept Therapeutics Incorporated (NASDAQ: CORT) for breaches of fiduciary duty, mismanagement, corporate waste, and violations of the Securities Exchange Act of 1934. Corcept is a pharmaceutical company that develops medications to treat severe metabolic, oncologic, and psychiatric disorders. Corcept's drug Korylm is a cortisol receptor blocker used to control
Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y 2020/02/21 19:25:00 Zacks Investment Research
Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.
Why Corcept (CORT) Could Beat Earnings Estimates Again 2020/02/19 17:10:06 Zacks Investment Research
Corcept (CORT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.